New eye drug OLN324 tested for wet AMD and diabetic swelling
NCT ID NCT07484074
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tested an investigational eye injection called OLN324 in 164 adults with either wet age-related macular degeneration (AMD) or diabetic macular edema (DME). The main goal was to check safety and how the drug moves in the body, with a preliminary look at whether it might improve vision. Participants received either OLN324 or an existing treatment (faricimab) to compare results.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- OLN324 (eye injection)
- What this could lead to
- If successful, this could lead to a new treatment option for wet AMD and diabetic macular edema, potentially reducing the need for frequent eye injections.
- What could go wrong
- This is an early Phase 1b trial focused on safety, so it is too soon to know if OLN324 works. The drug may not prove effective or could cause unexpected side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETIC MACULAR EDEMA (DME) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Abilene, TX
Abilene, Texas, 79606, United States
-
Arecibo, Puerto Rico
Arecibo, 00612-4368, Puerto Rico
-
Arlington, TX
Arlington, Texas, 76012, United States
-
Austin, TX
Austin, Texas, 78705, United States
-
Bellaire, TX
Bellaire, Texas, 77401, United States
-
Dallas, TX
Dallas, Texas, 75231, United States
-
Fort Myers, FL
Fort Myers, Florida, 33912, United States
-
Germantown, TN
Germantown, Tennessee, 38138, United States
-
Glendale, CA
Glendale, California, 91204, United States
-
Grand Rapids, MI
Grand Rapids, Michigan, 49546, United States
-
Hagerstown, MD
Hagerstown, Maryland, 21740, United States
-
Katy, TX
Katy, Texas, 77494, United States
-
Oak Forest, IL
Oak Forest, Illinois, 60452, United States
-
Pasadena, CA
Pasadena, California, 91107, United States
-
Phoenix, AZ
Phoenix, Arizona, 85016, United States
-
Plano, TX
Plano, Texas, 75075, United States
-
Reno, NV
Reno, Nevada, 89502, United States
-
Round Rock, TX
Round Rock, Texas, 78681, United States
-
Sacramento, CA
Sacramento, California, 95825, United States
-
Saint Petersburg, FL
St. Petersburg, Florida, 33711, United States
-
San Antonio, TX
San Antonio, Texas, 78240, United States
-
San Marcos, TX
San Marcos, Texas, 78666, United States
-
Schertz, TX
Schertz, Texas, 78154, United States
-
Springfield, OR
Springfield, Oregon, 97477, United States
-
The Woodlands, TX
The Woodlands, Texas, 77384, United States
-
Tulsa, OK
Tulsa, Oklahoma, 74114, United States
-
Wake Forest, NC
Wake Forest, North Carolina, 27587, United States
-
Walnut Creek, CA
Walnut Creek, California, 94598, United States
-
Waterford, CT
Waterford, Connecticut, 06385, United States
-
Winter Haven, FL
Winter Haven, Florida, 33880, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could eye drops replace injections for a leading cause of blindness?
- Could a daily eye gel replace injections for wet AMD?
- Can a new eye injection beat the current standard for diabetic vision loss?
- AI could predict which eye treatments work best for Diabetes-Related vision loss
- New eye drug EYE103 takes on lucentis in major trial for Diabetes-Related vision loss
- New dosing strategy could mean fewer eye injections for Diabetes-Related vision loss